Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 18,302	$ 8,683	$ 54,325	$ 26,727
General and administrative	7,852	5,919	24,563	14,776
Total operating expenses	26,154	14,602	78,888	41,503
Loss from operations	(26,154)	(14,602)	(78,888)	(41,503)
Other income (expense), net:
Other income, net	1,472	10	2,435	14
Change in fair value of the Series A redeemable convertible preferred stock tranche liability	0	0	0	(10,341)
Total other income (expense), net	1,472	10	2,435	(10,327)
Net loss	(24,682)	(14,592)	(76,453)	(51,830)
Unrealized loss on investments	(563)	0	(1,596)	0
Comprehensive loss	$ (25,245)	$ (14,592)	$ (78,049)	$ (51,830)
Net loss per share attributable to common stockholders-basic	$ (0.45)	$ (0.28)	$ (1.40)	$ (2.51)
Net loss per share attributable to common stockholders-diluted	$ (0.45)	$ (0.28)	$ (1.40)	$ (2.51)
Weighted-average shares used in computing net loss per share-basic	55,206,139	52,769,916	54,591,593	20,668,560
Weighted-average shares used in computing net loss per share-diluted	55,206,139	52,769,916	54,591,593	20,668,560